We’ve been reacting to our clients’ needs to help them think about workflow tools that assist with that what historically has been a very manual process. And the forecasting tool is something we have launched which will work with the IPMS systems to do just that and really enhance the value and increase the workflow tools we’re providing to that to that important customer base. So we’re doing it there. We talk about the acquisition we made in A&G. It’s a great tool. It’s a small acquisition, but a great technology that we bought that allows guided discovery in educational tools to help professors in their content as they reach out to their students. And I have two college students so I can really imagine, Owen, how this works. It’s going to help, it’s going to help students as they test their knowledge, answer a question.
And the way they answer would then really to further bespoke questions to really test that students’ knowledge. I think it’s going to be the way of education and the way of the future and we are investing heavily in those areas. Those are just a few examples. Lots more to come. We’ll be sharing that in future calls. Thank you.
Owen Lau: Thanks.
Operator: Our next question comes from the line of Ashish Sabadara with RBC. Ashish, your line is now open.
Ashish Sabadra : Thanks for taking my question, and thanks for providing more detailed Q4 organic guidance. Question that was just focused on one of the headwinds called out with the commercial budget and the fourth quarter is seasonally strong quarter for commercialization revenues, my understanding particularly the RWD and the DRT business. I was just wondering what to assume from that business perspective? And how is the transition the progress on the platform to deliver these therapeutic RWD solution directly to the end-users? How is that progressing? Thanks.
Jonathan Collins : Yeah thank you for the question, Ashish. And you are spot on the fourth quarter is a seasonally higher quarter for our life sciences transactional business. Certainly includes the commercialization products and services that we describe even on the R&D side. We are usually looking to capture year end spending. As we’ve talked about earlier in the year, particularly on commercialization, drug approvals last year were down, which puts us in a position where commercialization budgets are lower this year. We’ve seen that play out through the year. We have better line of sight into what we think the year end availability of funds will be. And we trim the expectation there just modestly we are only talking a couple few million dollars as a part of the change in the organic outlook or the current indication for Q4.
So, that’s really what the driver is there. To your second point, we’ve been very focused from a product development standpoint this year on building out better content, higher quality information with tools that will be relevant for our life sciences customers. We’ve made really good progress. We’ve got the launch of the first module on track to go out in the fourth quarter of this year and there’ll be more to come next year. I expected that we’ll be in a position at yearend earnings in early March to talk more about the plans for 2024. So stay tuned for that. But thank you for the question.
Mark Donohue : Thank you. Next question please.
Operator: Thank you for your question. [Operator Instructions] Our next question comes from the line of Peter Christiansen with Citi. Peter, your line is now open.
Peter Christiansen : Thank you. Good morning. Thanks for the question. I just wanted to follow up on the previous question. As we think about the setup for discretionary revenue – discretionary spending from your clients, perhaps maybe outside of life sciences, just wondering if you can frame that in terms of maybe what you’re seeing maybe on the A&G side as we get into the fourth quarter and should we be mindful of any year-over-year comparisons for fourth quarter? Thank you.
